ResearchMoz

Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

GlobalData
Published Date » 2012-06-18
No. Of Pages » 65
   
 GlobalData, the industry analysis specialist, has released its new report, Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases,...
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Hepatitis A Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.2.1 Historical Vaccination Coverage (2006-2011) 9
2.2.2 Forecast Vaccination Coverage (2011-2019) 9
2.3 Prognosis 10
2.4 Etiology 10
2.5 Pathophysiology 12
2.6 Signs and Symptoms 13
2.7 Diagnosis 14
2.8 Treatment and Management Options 16
2.9 Referral Pathway 18
2.10 GlobalData Pipeline Report Guidance 20

3 Hepatitis A Preventive Vaccines - Market Characterization 21
3.1 Global Hepatitis A Preventive Vaccines Market Size (2006-2011) 21
3.2 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Global 22
3.3 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The US 23
3.4 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The US 24
3.5 Hepatitis A Preventive Vaccines Market Size (2006-2011) - France 25
3.6 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - France 26
3.7 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Germany 27
3.8 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Germany 28
3.9 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Italy 29
3.10 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Italy 30
3.11 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Spain 31
3.12 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Spain 32
3.13 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The UK 33
3.14 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The UK 34
3.15 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Japan 35
3.16 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Japan 36
3.17 Drivers and Barriers for the Hepatitis A Preventive Vaccines Market 37
3.17.1 Drivers for the Hepatitis A Preventive Vaccines Market 37
3.17.2 Barriers for the Hepatitis A Preventive Vaccines Market 37
3.18 Opportunity and Unmet Need Analysis 38
3.19 Key Takeaway 39

4 Hepatitis A Preventive Vaccines - Competitive Assessment 40
4.1 Overview 40
4.2 Strategic Competitor Assessment 40
4.3 Product Profiles for the Major Marketed class of Products in the Hepatitis A Market 41
4.3.1 Havrix 41
4.3.2 Vaqta 42
4.3.3 Twinrix 44
4.3.4 Ambirix 45
4.3.5 Avaxim 46
4.3.6 Epaxal 46
4.4 Key Takeaway 47

5 Hepatitis A Preventive Vaccines - Clinical Trials Mapping 48
5.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 48
5.2 Clinical Trials by Phase 49
5.3 Clinical Trials by Trial Status 50
5.4 Prominent Sponsors 51
5.5 Clinical Trials by Overall Sponsors 52
5.6 Top Companies Participating in Hepatitis A Preventive Vaccines Clinical Trials 53

6 Hepatitis A Preventive Vaccines - Strategic Assessment 54
6.1 Key Events Impacting the Future Market 54
6.2 Hepatitis A Preventive Vaccines: Implications for Future Market Competition 55

7 Hepatitis A Preventive Vaccines - Future Players 56
7.1 Introduction 56
7.2 Company Profiles 56
7.2.1 GlaxoSmithKline 56
7.2.2 Merck & Co 56
7.2.3 Crucell 57

8 KOL Insights 58

9 Hepatitis A Preventive Vaccines - Appendix 59

9.1 Market Definitions 59
9.2 Abbreviations 59
9.3 Bibliography 60
9.4 Methodology 61
9.4.1 Coverage 61
9.4.2 Secondary Research 61
9.4.3 Forecasting 62
9.4.4 Primary Research 64
9.4.5 Expert Panel Validation 65
9.5 Contact Us 65
9.6 Disclaimer 65

List of Tables


Table 1: Comparison between Hepatitis A, B and C 7
Table 2: HAV Endemicity by Region 8
Table 3: Vaccination Coverage (In Percentage) 9
Table 4: Vaccination Coverage (In Percentage) 9
Table 5: History and Physical Examination 14
Table 6: Laboratory and Other Studies for Hepatitis A 15
Table 7: Differential Diagnosis of hepatitis A 15
Table 8: Havrix Dosage and Schedule for Vaccination 16
Table 9: Vaqta Dosage and Schedule for Vaccination 16
Table 10: Twinrix Dosage and Schedule for Vaccination 16
Table 11: UK Guidelines For Hepatitis A Vaccination 17
Table 12: Japanese Hepatitis A Vaccine, Dosage and Schedule 17
Table 13: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011 21
Table 14: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019 22
Table 15 Hepatitis A Preventive Vaccines Market, The US, Revenue ($m), 2006-2011 23
Table 16: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019 24
Table 17: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011 25
Table 18: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019 26
Table 19: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011 27
Table 20: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019 28
Table 21: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011 29
Table 22: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019 30
Table 23: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011 31
Table 24: Hepatitis A Preventive Vaccines, Spain, Forecast ($m), 2011-2019 32
Table 25: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011 33
Table 26: Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019 34
Table 27: Hepatitis A Market, Japan, Revenue ($m), 2006-2011 35
Table 28: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019 36
Table 29: Hepatitis A Preventive Vaccines - Clinical Trials by Region/ Country, 2012 48
Table 30: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012 49
Table 31: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012 50
Table 32: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012 51
Table 33: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012 52
Table 34: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012 53

List of Figures


Figure 1: Prevalence of Hepatitis A Virus by Region 8
Figure 2: Incidence of Hepatitis A, 1980-2009 10
Figure 3: Pathophysiology of Hepatitis A 12
Figure 4 : Symptoms of Hepatitis A infection 13
Figure 5: Referral Pathway for HAV Vaccination 18
Figure 6: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 19
Figure 7: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011 21
Figure 8: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019 22
Figure 9 Hepatitis A Preventive Vaccines, The US, Revenue ($m), 2006-2011 23
Figure 10: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019 24
Figure 11: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011 25
Figure 12: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019 26
Figure 13: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011 27
Figure 14: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019 28
Figure 15: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011 29
Figure 16: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019 30
Figure 17: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011 31
Figure 18: Hepatitis A Preventive Vaccines Market, Spain, Forecast ($m), 2011-2019 32
Figure 19: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011 33
Figure 20 : Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019 34
Figure 21 : Hepatitis A Preventive Vaccines Market, Japan, Revenue ($m), 2006-2011 35
Figure 22: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019 36
Figure 23: Opportunity and Unmet Need in the Hepatitis A Preventive Vaccines Market, 2012 38
Figure 24: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 39
Figure 25: Hepatitis A Preventive Vaccines - Strategic Competitor Assessment, 2012 41
Figure 26: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 47
Figure 27: Hepatitis A Preventive Vaccines - Clinical Trials by Country, 2012 48
Figure 28: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012 49
Figure 29: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012 50
Figure 30: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012 51
Figure 31: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012 52
Figure 32: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012 53
Figure 33: Hepatitis A Preventive Vaccines Market - Drivers and Restraints 2012 54
Figure 34: Implications for Future Market Competition in Hepatitis A Preventive Vaccines Market, 2012 55
Figure 35: Hepatitis A Preventive Vaccines - Marketed Products by Company, 2012 56
Figure 36: KOL Insights, Hepatitis A Preventive Vaccines, Major Market 58
Figure 37: GlobalData Market Size Estimation 62
Figure 38 : GlobalData Market Forecasting Model 64

Upcoming Reports:

Acetaldehyde Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The global value of the acetaldehyde market in terms of production is estimated to reach 1.33 million tons towards the end of 2012. Asia Pacific is the global leader for the acetaldehyde market with China holding the world’s largest manufacturer’s tag. The Asia Pacific region is followed by the European and the North American regions. Acetaldehyde market growth is on a downward slope for the North American and the European regions, however, the Asia Pacific region is experiencing an indolent growth. The manufacturers are coming up with more commercially...
PEM Fuel Cells Materials (used for Proton Exchange Membranes and Membrane Electrode Assemblies) Market - Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The global market for components of proton exchange membranes (PEM) and membrane electrode assemblies (MEA) used in PEM Fuel cells (PEMFC) is witnessing a trend of rising demand. The market is expected to record a compounded growth of approximately 21.1% from 2012 to 2018. The key factors influencing the market growth are growing environmental problems and depleting conventional fuel resources. This has resulted in the need to find alternative energy resources, and fuel cells have been instrumental in meeting the diverse requirements.  The growing demand for efficient,...
Luxury Goods Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The luxury goods market is expected to grow by 7% by the end of 2012 despite the economic slowdown. The major reason behind this significant rise in the luxury goods industry is the rising concern of people over style and personal attire. Changing lifestyle and rising living standards are mainly driving the growth of this market.  China is the leading manufacturer of luxury goods and the predicted growth rate of the Chinese market is about 18% to 20%. The luxury goods industry is forecast to grow between 5% and 7% in America and 2% and 4% in Europe in 2012. Japan, which...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Blackstone Invests $800 Million in Asian Oil-Based Energy Company
Jul 31, 2014  
Blackstone Energy Partners announced to invest $800 million in an Asian based energy company that is led by former industry executives.  Blackstone is popularly considered a part of the world’s largest administrator of alternatives to financial stocks and bonds. New York-based managing director, Angelo Acconcia of Blackstone Energy Partners said in an interview that Tamarind...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...